BXP vs. LSE, WPY, AHT, LAND, TW, SIR, SAFE, CLIN, EVR, and BGSC
Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include London Stock Exchange Group plc (LSE.L) (LSE), Worldpay (WPY), Ashtead Group (AHT), Land Securities Group (LAND), Taylor Wimpey (TW), Secure Income REIT (SIR), Safestore (SAFE), Clinigen Group (CLIN), EVRAZ (EVR), and BMO Global Smaller Companies (BGSC). These companies are all part of the "trading" industry.
Beximco Pharmaceuticals vs.
Beximco Pharmaceuticals (LON:BXP) and London Stock Exchange Group plc (LSE.L) (LON:LSE) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
Beximco Pharmaceuticals has higher revenue and earnings than London Stock Exchange Group plc (LSE.L). London Stock Exchange Group plc (LSE.L) is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Beximco Pharmaceuticals has a net margin of 13.71% compared to London Stock Exchange Group plc (LSE.L)'s net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 13.12% beat London Stock Exchange Group plc (LSE.L)'s return on equity.
1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
London Stock Exchange Group plc (LSE.L) received 662 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 71.83% of users gave London Stock Exchange Group plc (LSE.L) an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote.
Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 8.7%. London Stock Exchange Group plc (LSE.L) pays an annual dividend of GBX 73 per share. Beximco Pharmaceuticals pays out 32.2% of its earnings in the form of a dividend. London Stock Exchange Group plc (LSE.L) pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Beximco Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.
In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled London Stock Exchange Group plc (LSE.L)'saverage media sentiment score.
Summary
Beximco Pharmaceuticals beats London Stock Exchange Group plc (LSE.L) on 7 of the 11 factors compared between the two stocks.
Get Beximco Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beximco Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:BXP) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy BXP Stock Free BXP Stock Alerts